If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.


Drug Discovery

Hexagon Bio gets $47 million to mine fungus genomes for new drugs

The series A financing will allow the company to grow its drug discovery platform to treat cancers and infectious diseases

by Megha Satyanarayana
September 17, 2020 | A version of this story appeared in Volume 98, Issue 36

An image of the founders of Hexagon Bio.
Credit: Georgia Campbell/Hexagon Bio
Hexagon Bio just sealed $45 million in series A investment to build on its fungal drug discovery program.

Hexagon Bio, a Menlo Park, California–based company trying to develop drugs from natural defense compounds secreted by fungi, has raised $47 million in series A financing. The funds will be used to further develop the company’s drug discovery platform and to build out its discovery team, CEO Maureen Hillenmeyer says.

The 26-person company just hired oncology drug discovery expert Tod Smeal to be its chief scientific officer.

Hexagon, one of C&EN’s 10 Start-Ups to Watch in 2018, uses a combination of genomics and computational biology to find fungal toxins that might serve as starting points for drugs for cancer and infectious diseases.

Hillenmeyer says there are about 5 million species of fungi, many of which protect themselves by secreting potent toxins that can enter other cells. An example of this is penicillin. But as fungi develop these toxins, they also mutate the protein target within their own cells to prevent accidental self-poisoning.

Humans and fungi have about 6,000 genes in common, so by searching the millions of fungal genomes for toxins and the mutated target protein, Hexagon scientists can suggest which human protein the toxin would target and then develop the toxin into a drug.

About 5,000 fungal genomes are already sequenced and available, so Hexagon is sequencing many of the remaining genomes and feeding those data through its computational system.

Hillenmeyer says the firm is still sifting through anticancer candidates. But fungal toxins check two important boxes in drug discovery: they’re effective, and they can enter cells.

In addition to its work in oncology, Hexagon is also looking for antifungals to treat secondary infections.


This story was updated on Sept. 17, 2020, to correct the location of Hexagon Bio. The firm is based in Menlo Park, California, not Cambridge, Massachusetts.



This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.